Singapore, Feb. 9 -- A study was recently conducted to support evidence-based decision making in Thailand and to help policymakers in low and middle income countries evaluate screening options for detecting tuberculosis(TB)infection.

The analysis modeled one-time TB infection screening in adults living with HIV and projected lifetime costs and health outcomes based on Thai epidemiological and cost data. According to the published findings,Interferon-gamma releasing assays (IGRAs)such as QuantiFERON-TB Gold Plus (QFT-Plus) by Qiagen, were associated with a lower modeled lifetime risk of progression to active TB, approximately 41% lower thanTuberculin Skin Test(TST), while also demonstrating lower projected lifetime costs per individual sc...